Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer
June 24th 2022Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.
Read More